Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2013 December;65(4) > Minerva Urologica e Nefrologica 2013 December;65(4):249-62

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

  ADVANCES IN UROLOGY - PART I 

Minerva Urologica e Nefrologica 2013 December;65(4):249-62

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Intravesical glycosaminoglycans in the management of chronic cystitis

Iacovelli V., Topazio L., Gaziev G., Bove P., Vespasiani G., Finazzi Agrò E.

Department of Urology, Tor Vergata University of Rome, Rome, Italy


PDF


In this article we review the current status of evidence on the clinic applications of glycosaminoglycans (GAGs) in urology, with particular emphasis on the therapeutic use in all the chronic forms of cystitis. The so called “bladder layer” is mainly composed by chondroitin sulphate, dermatan sulphate and heparan sulphate. Demages of this mucus film seem to be involved in the pathogenesis of several bladder diseases. Hence, GAG replenishment therapy is widely accepted as a therapy for interstitial cystitis/ bladder pain syndrome (IC/BPS), recurrent urinary tract infections (UTIs), radiation and chemo-immunotherapy cystis and overactive bladder (OAB). A MEDLINE search from the first clinical application in 1996 allowed us to find a total of 33 works regarding the use of intravesical GAGs. Although the evidences regarding GAG replenishment therapy are very encouraging in all the forms of chronic cystitis, well-powered randomized clinical trials are needed to better comprehend the exact role of this treatment.

top of page